Related Companies

• EpiStem Holdings

Related Indices

• FTSE AIM All-Share

Related Sectors

• Pharmaceuticals & Biotechnology

News for Spread Betters

Previous

Next

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here.

News for Spread Betters

Previous

Next

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here.

Unsecured Loans

Previous

Next

Lighten the load of all those repayments with a low rate unsecured loan. This month's selected offers:

1. Barclays Loans
2. Halifax Loans

AMEX Platinum

Previous

Next

Money back on your spendings? With American Express Platinum MoneyBack card, you can get

• 5% Money Back* during your first 3 months, then
• standard Money Back rate up to 1.5% with
• typical APR 18.9% variable

Why look further? Apply now!

Digital Look's Best Picks

Previous

Next

Your money can work for you! Get it going with one of this month’s high interest current accounts:

1. A&L Premier Direct
2. Coventry First Account
3. Co-operative Current Plus

Date: Monday 06 Oct 2008

LONDON (ShareCast) - Manchester based biotechnology firm EpiStem said full-year pre-tax loss widened but trading in the first three months of the new financial year has
been strong.

The group, which specialises in oncology and gastrointestinal diseases, said pre-tax loss grew to £1.33m for the year ended 30 June 2008 compared with just under £1.20m the year before. Revenues rose to £2.07m from £1.36m previously.

Current trading has been strong with revenues 20% ahead of the comparative period last year, it said.

"Despite the difficult market and trading conditions, the outlook for Epistem is increasingly positive, although we remain attentive to the challenges ahead," the group added.

• News Channel